Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Chronic Inflammatory Bowel Disease | Research

Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores

Authors: Tiago Lima Capela, Vítor Macedo Silva, Marta Freitas, Cátia Arieira, Tiago Cúrdia Gonçalves, Francisca Dias de Castro, Joana Magalhães, José Cotter

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Inflammatory bowel disease (IBD) patients have a higher risk of metabolic dysfunction-associated fatty liver disease (MAFLD) compared with the general population. However, it is not known whether available non-invasive hepatic steatosis scores are useful in predicting MAFLD in IBD patients. We aimed to analyze the performances of MAFLD screening score (MAFLD-S), Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI) and Clinical Prediction Tool for NAFLD in Crohn’s Disease (CPN-CD), in identifying MAFLD in IBD patients.

Methods

A cross-sectional study was carried out including consecutive adult IBD outpatients submitted to transient elastography (TE). MAFLD criteria were assessed, and hepatic steatosis (HS) was defined by a controlled attenuation parameter (CAP) >248 dB/m using TE. MAFLD-S, FLI, HSI, and CPN-CD were calculated and their accuracy for the prediction of MAFLD was evaluated through their areas under the receiver-operating characteristic (AUROC) curves.

Results

Of 168 patients, body mass index ≥25, type 2 diabetes mellitus, dyslipidemia and arterial hypertension were present in 76 (45.2%), 10 (6.0%), 53 (31.5%), 20 (11.9%), respectively. HS was identified in 77 (45.8%) patients, of which 65 (84.4%) fulfilled MAFLD criteria. MAFLD-S (AUROC, 0.929 [95% CI, 0.888-0.971]) had outstanding and FLI (AUROC, 0.882 [95% CI, 0.830–0.934]), HSI (AUROC, 0.803 [95% CI, 0.736–0.871]), and CPN-CD (AUROC, 0.822 [95% CI, 0.753–0.890) had excellent discrimination in predicting MAFLD.

Conclusions

MAFLD-S, FLI, HSI and CPN-CD scores can accurately identify MAFLD in IBD patients, allowing the selection of those in whom hepatic steatosis and metabolic risk factors assessment may be particularly beneficial.
Literature
1.
go back to reference Vegh Z, Kurti Z, Lakatos PL. Epidemiology of inflammatory bowel diseases from west to east. J Dig Dis. 2017;18(2):92–8.CrossRefPubMed Vegh Z, Kurti Z, Lakatos PL. Epidemiology of inflammatory bowel diseases from west to east. J Dig Dis. 2017;18(2):92–8.CrossRefPubMed
2.
go back to reference Rodriguez-Duque JC, Calleja JL, Iruzubieta P, Hernandez-Conde M, Rivas-Rivas C, Vera MI, et al. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. Clin Gastroenterol Hepatol. 2023;21(2):406–14 e7. Rodriguez-Duque JC, Calleja JL, Iruzubieta P, Hernandez-Conde M, Rivas-Rivas C, Vera MI, et al. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. Clin Gastroenterol Hepatol. 2023;21(2):406–14 e7.
3.
go back to reference Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999–2014e.CrossRefPubMed Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999–2014e.CrossRefPubMed
4.
go back to reference Attia D, Gomaa A, Abdel AS. Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD. Hepatology. 2022;76(5):E100.CrossRefPubMed Attia D, Gomaa A, Abdel AS. Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD. Hepatology. 2022;76(5):E100.CrossRefPubMed
5.
go back to reference Zamani M, Alizadeh-Tabari S, Singh S, Loomba R. Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(8):894–907.CrossRefPubMedPubMedCentral Zamani M, Alizadeh-Tabari S, Singh S, Loomba R. Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(8):894–907.CrossRefPubMedPubMedCentral
6.
go back to reference Ritaccio G, Stoleru G, Abutaleb A, Cross RK, Shetty K, Sakiani S, et al. Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare. Dig Dis Sci. 2021;66(9):3186–91.CrossRefPubMed Ritaccio G, Stoleru G, Abutaleb A, Cross RK, Shetty K, Sakiani S, et al. Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare. Dig Dis Sci. 2021;66(9):3186–91.CrossRefPubMed
7.
go back to reference Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2021;27(6):947–55.CrossRefPubMed Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2021;27(6):947–55.CrossRefPubMed
8.
go back to reference Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis. 2013;19(3):599–613. Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis. 2013;19(3):599–613.
9.
go back to reference Noorian S, Jeon Y, Nguyen MT, Sauk J, Limketkai BN. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. Inflamm Bowel Dis. 2022;28(6):878–87.CrossRefPubMed Noorian S, Jeon Y, Nguyen MT, Sauk J, Limketkai BN. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. Inflamm Bowel Dis. 2022;28(6):878–87.CrossRefPubMed
10.
go back to reference Aggarwal M, Garg R, Parthasarthy G, Nowacki AS, Padival R, McCullough A, et al. Crohn's Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2023;68(3):1006–15. Aggarwal M, Garg R, Parthasarthy G, Nowacki AS, Padival R, McCullough A, et al. Crohn's Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2023;68(3):1006–15.
11.
go back to reference European Association for the Study of the Liver, Electronic address eee, Clinical Practice Guideline P, Chair, representative EGB, Panel m. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659–89.CrossRef European Association for the Study of the Liver, Electronic address eee, Clinical Practice Guideline P, Chair, representative EGB, Panel m. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659–89.CrossRef
12.
go back to reference Sourianarayanane A, McCullough AJ. Accuracy of steatosis and fibrosis NAFLD scores in relation to vibration controlled transient elastography: An NHANES analysis. Clin Res Hepatol Gastroenterol. 2022;46(7):101997.CrossRefPubMed Sourianarayanane A, McCullough AJ. Accuracy of steatosis and fibrosis NAFLD scores in relation to vibration controlled transient elastography: An NHANES analysis. Clin Res Hepatol Gastroenterol. 2022;46(7):101997.CrossRefPubMed
13.
go back to reference Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.CrossRefPubMedPubMedCentral Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.CrossRefPubMedPubMedCentral
14.
go back to reference Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–8.CrossRefPubMed Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–8.CrossRefPubMed
15.
go back to reference McHenry S, Tirath A, Tsai R, Sharma Y, Flores AG, Davidson NO, et al. Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn’s Disease. Inflamm Bowel Dis. 2020;26(12):1917–25. McHenry S, Tirath A, Tsai R, Sharma Y, Flores AG, Davidson NO, et al. Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn’s Disease. Inflamm Bowel Dis. 2020;26(12):1917–25.
16.
go back to reference Ruiz-Manriquez J, Olivas-Martinez A, Chávez-García LC, Fernández-Ramírez A, Moctezuma-Velazquez C, Kauffman-Ortega E, et al. Prevalence of Metabolic-associated Fatty Liver Disease in Mexico and Development of a Screening Tool: The MAFLD-S Score. Gastro Hep Advances. 2022;1(3):352–8.CrossRef Ruiz-Manriquez J, Olivas-Martinez A, Chávez-García LC, Fernández-Ramírez A, Moctezuma-Velazquez C, Kauffman-Ortega E, et al. Prevalence of Metabolic-associated Fatty Liver Disease in Mexico and Development of a Screening Tool: The MAFLD-S Score. Gastro Hep Advances. 2022;1(3):352–8.CrossRef
17.
go back to reference Castellana M, Donghia R, Guerra V, Procino F, Lampignano L, Castellana F, et al. Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis. J Clin Med. 2021;10(9):1877. Castellana M, Donghia R, Guerra V, Procino F, Lampignano L, Castellana F, et al. Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis. J Clin Med. 2021;10(9):1877.
18.
go back to reference Arieira C, Monteiro S, Xavier S, Dias de Castro F, Magalhaes J, Moreira MJ, et al. Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the difference. Eur J Gastroenterol Hepatol. 2019;31(8):998–1003.CrossRefPubMed Arieira C, Monteiro S, Xavier S, Dias de Castro F, Magalhaes J, Moreira MJ, et al. Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the difference. Eur J Gastroenterol Hepatol. 2019;31(8):998–1003.CrossRefPubMed
19.
go back to reference Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144–64.CrossRefPubMed Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144–64.CrossRefPubMed
20.
go back to reference Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384–413.CrossRefPubMed Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384–413.CrossRefPubMed
21.
go back to reference von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9.CrossRef von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9.CrossRef
22.
go back to reference Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3–25. Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3–25.
23.
go back to reference Lemoine M, Shimakawa Y, Njie R, Njai HF, Nayagam S, Khalil M, et al. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia. Aliment Pharmacol Ther. 2014;39(2):188–96.CrossRefPubMed Lemoine M, Shimakawa Y, Njie R, Njai HF, Nayagam S, Khalil M, et al. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia. Aliment Pharmacol Ther. 2014;39(2):188–96.CrossRefPubMed
24.
go back to reference Ferraioli G, Filice C, Castera L, Choi BI, Sporea I, Wilson SR, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. Ultrasound Med Biol. 2015;41(5):1161–79.CrossRefPubMed Ferraioli G, Filice C, Castera L, Choi BI, Sporea I, Wilson SR, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. Ultrasound Med Biol. 2015;41(5):1161–79.CrossRefPubMed
25.
go back to reference Mehta M, Singh P, De A, Duseja A. Poor Applicability of MAFLD Criteria for Lean Patients with NAFLD in Real-life Practice. J Clin Exp Hepatol. 2022;12:S34.CrossRef Mehta M, Singh P, De A, Duseja A. Poor Applicability of MAFLD Criteria for Lean Patients with NAFLD in Real-life Practice. J Clin Exp Hepatol. 2022;12:S34.CrossRef
26.
go back to reference Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022–30.CrossRefPubMed Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022–30.CrossRefPubMed
27.
go back to reference Xu Z, Li H, Tian S, Wu J, Li X, Liu ZL, et al. Blood biomarkers for the diagnosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease. J Hepatol. 2020;73(5):1264–5.CrossRefPubMed Xu Z, Li H, Tian S, Wu J, Li X, Liu ZL, et al. Blood biomarkers for the diagnosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease. J Hepatol. 2020;73(5):1264–5.CrossRefPubMed
28.
go back to reference Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40(10):1209–22.CrossRefPubMed Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40(10):1209–22.CrossRefPubMed
29.
go back to reference Saroli Palumbo C, Restellini S, Chao CY, Aruljothy A, Lemieux C, Wild G, et al. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. Inflamm Bowel Dis. 2019;25(1):124–33.CrossRefPubMed Saroli Palumbo C, Restellini S, Chao CY, Aruljothy A, Lemieux C, Wild G, et al. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. Inflamm Bowel Dis. 2019;25(1):124–33.CrossRefPubMed
30.
go back to reference Steed H, Walsh S, Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside. Scotland Obes Facts. 2009;2(6):370–2.CrossRefPubMed Steed H, Walsh S, Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside. Scotland Obes Facts. 2009;2(6):370–2.CrossRefPubMed
31.
go back to reference Zou ZY, Shen B, Fan JG. Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(11):1764–72.CrossRefPubMed Zou ZY, Shen B, Fan JG. Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(11):1764–72.CrossRefPubMed
32.
go back to reference Sagami S, Ueno Y, Tanaka S, Fujita A, Hayashi R, Oka S, et al. Significance of non-alcoholic fatty liver disease in Crohn’s disease: A retrospective cohort study. Hepatol Res. 2017;47(9):872–81. Sagami S, Ueno Y, Tanaka S, Fujita A, Hayashi R, Oka S, et al. Significance of non-alcoholic fatty liver disease in Crohn’s disease: A retrospective cohort study. Hepatol Res. 2017;47(9):872–81.
33.
go back to reference Oh HJ, Kim TH, Sohn YW, Kim YS, Oh YR, Cho EY, et al. Association of serum alanine aminotransferase and gamma-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease. Korean J Hepatol. 2011;17(1):27–36.CrossRefPubMedPubMedCentral Oh HJ, Kim TH, Sohn YW, Kim YS, Oh YR, Cho EY, et al. Association of serum alanine aminotransferase and gamma-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease. Korean J Hepatol. 2011;17(1):27–36.CrossRefPubMedPubMedCentral
35.
go back to reference Schroder T, Schmidt KJ, Olsen V, Moller S, Mackenroth T, Sina C, et al. Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment. Eur J Gastroenterol Hepatol. 2015;27(6):698–704.CrossRefPubMed Schroder T, Schmidt KJ, Olsen V, Moller S, Mackenroth T, Sina C, et al. Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment. Eur J Gastroenterol Hepatol. 2015;27(6):698–704.CrossRefPubMed
36.
go back to reference Han AL, Lee HK. Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease. Metabolites. 2022;12(7):664. Han AL, Lee HK. Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease. Metabolites. 2022;12(7):664.
37.
go back to reference Liu Y, Liu S, Huang J, Zhu Y, Lin S. Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study. J Gastroenterol Hepatol. 2022;37(5):938–45.CrossRefPubMed Liu Y, Liu S, Huang J, Zhu Y, Lin S. Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study. J Gastroenterol Hepatol. 2022;37(5):938–45.CrossRefPubMed
38.
go back to reference Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(8):1937–44.CrossRefPubMed Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(8):1937–44.CrossRefPubMed
Metadata
Title
Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores
Authors
Tiago Lima Capela
Vítor Macedo Silva
Marta Freitas
Cátia Arieira
Tiago Cúrdia Gonçalves
Francisca Dias de Castro
Joana Magalhães
José Cotter
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02988-w

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.